Either we get ahead of this crisis or watch a generation of Americans be swept into the devastating grip of disease.
Celebrating the stories of PATF and Allies FEATURING: Kathi Boyle, Stuart Fisk, Tammy Frech, DJ Stemmler & Pam Vingle, Nachum Golan & Steve Hough, Alan Jones, ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Zacks Investment Research on MSN
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...
Today, Seema Sahay is Head of Division of Social Behavioural Research at the Indian Council of Medical Research, National Institute of Translational Virology & AIDS Research (NARI), Pune, India.
Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...
The investigational oral therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor, in a single tablet ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results